By Sheeba M. | April 25, 2026
“Marijuana Rescheduling: Initial Rally Fades as Market Digests Reality”
TL;DR
Cannabis stocks spiked on DOJ reclassification to Schedule III but retreated sharply as investors realize the immediate regulatory wins are limited. Schedule III removes IRS Code Section 280E restrictions—a real tax benefit—but doesn’t resolve funding or interstate commerce barriers. Market is pricing in a slower timeline for transformative reform.
—
The Rally That Wasn’t
When news broke that the Trump Administration would reclassify marijuana from Schedule I to Schedule III, cannabis investors erupted. Tilray Brands (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB) all spiked sharply. But the party didn’t last long.
By the end of the trading day, shares had retreated. By now, most stocks are back below the rescheduling announcement levels. It’s the classic “sell the news” pattern—and it tells us something important about market expectations vs. reality.
—
What Rescheduling Actually Changes (And Doesn’t)
The Win: Schedule III removal of IRS Code Section 280E restrictions means cannabis companies can finally deduct ordinary business expenses on their tax returns. For profitable MSOs, this is a meaningful tax benefit—potentially improving after-tax returns by 10-15% for some operators.
The Reality Check:
- Interstate commerce remains illegal (SAFE Act still needed)
- Banking access still requires additional legislation
- State-level prohibition hasn’t changed
- Federal cultivation limits still apply
- DEA still has enforcement authority
In short: It’s progress. It’s not transformation.
—
The Sell-the-News Pattern
Market analysts are calling this a classic “sell the news” reaction. Dan Ahrens, portfolio manager of AdvisorShares Pure U.S. Cannabis ETF, summed it up:
> “The sector’s weakness looked partly like a ‘sell the news’ reaction and some short-term profit taking, but was driven mainly by investors digesting the next procedural step needed to complete rescheduling.”
Translation: The market got ahead of itself. Investors had priced in bigger wins. When rescheduling didn’t immediately unlock banking, interstate commerce, or federal legalization, sellers outnumbered buyers.
—
What Comes Next
The procedural steps for full rescheduling implementation will take months. Public comment periods, regulatory guidance, DEA rule-making—the timeline is measured in quarters, not weeks.
Meanwhile, the cannabis industry still faces:
- Refinancing pressures (many MSOs have 2026-2027 maturities)
- Low equity valuations (stock-based deals are unattractive)
- Distressed M&A (April 2026 saw 11 transactions, mostly forced sales)
- Consumer behavior shifts (GLP-1 weight-loss drugs reducing cannabis consumption)
—
The Takeaway
Rescheduling is a genuine positive for the sector. But it’s not the catalyst that transforms valuations overnight. Smart investors should expect a slow, grinding recovery tied to:
1. Actual implementation of Schedule III benefits
2. SAFE Act passage (still years away likely)
3. Operational consolidation and margin improvement
4. Consumer demand normalization post-GLP-1 boom
For now, the initial rally revealed more about investor expectations than about the cannabis market’s fundamentals.
—
By Sheeba M. | April 25, 2026